BioSpace News Archive

Amgen announced three new data sets from its thoracic oncology portfolio that will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer from August 6-9 in Vienna, Austria.

BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs.

CStone Pharmaceuticals, announced the presentation of the final progression-free survival analysis results from the registrational GEMSTONE-301 study of sugemalimab as a consolidation therapy in patients with unresectable stage III non-small cell lung cancer whose disease had not progressed after concurrent or sequential chemoradiotherapy at the IASLC 2022 World Conference on Lung Cancer.

BiomX Inc. announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, to report second quarter 2022 financial results and provide business updates.

HUTCHMED Limited announces that the pivotal global Phase 3 FRESCO-2 trial evaluating the investigational use of fruquintinib met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer.

Innovent Biologics, Inc. announces that the first patient with diabetic macular edema has been successfully dosed in the Phase 1 study of IBI324, a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.

ImmVira’s brand new oncolytic herpes simplex virus product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation from U.S. Food and Drug Administration.

Ascletis Pharma Inc. announces the completion of first patient dosing in the U.S. Phase I clinical trial of ASC61, an oral PD-L1 small molecule inhibitor prodrug, for treatment of advanced solid tumors.

Transcenta Holding Limited announces the appointment of Dr. Caroline Germa as the company’s Executive Vice President, Global Medicine Development and Chief Medical Officer, reporting to Dr. Xueming Qian, CEO.

NaoTrac, the CE-certified neurosurgical navigation robot, achieved approval from Taiwan’s Food and Drug Administration in July 2022, and is planned for submission to the FDA for clearance by the end of 2022.